Zamaneh Mikhak, M.D.
Chief Medical Officer
Dr. Mikhak is a physician-scientist Board Certified in Allergy and Immunology with over 23 years of clinical experience and 18 years of basic and translational research experience. Her industry experience spans across big pharma and small biotech, including biologics and small molecules in rare and common diseases in multiple therapeutic areas. Prior to joining TFF Pharmaceuticals, Dr. Mikhak served as Senior Vice President, Head of Clinical Development at Cogent Biosciences where she oversaw the Clinical Development function across the Company’s major portfolio programs. Prior to Cogent, she served as Vice President, Clinical Development at Boston Pharmaceuticals where she led the strategy and clinical development of Avizakimab and executed a global Phase 2 study in systemic lupus erythematosus during the early stages of the COVID-19 pandemic. As Senior Director at Kiniksa Pharmacueticals, Dr. Mikhak led the Vixarelimab program from the pre-clinical stage into First-In-Human and then Phase 2 studies in seven indications and generated data for a successful IPO. At Sanofi/Genzyme, Dr. Mikhak served as a Translational Medicine Lead across the portfolio and led a food allergy program. Dr. Mikhak was an Assistant Professor at Harvard Medical School and an NIH funded Principal Investigator at Massachusetts General Hospital prior to joining industry. She completed her fellowship in Pediatric Allergy/Immunology at Boston Children’s Hospital, earned her M.D. from the University of Pennsylvania School of Medicine and earned her Bachelor of Arts degree in Biology from Boston University.